Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERU phase 3 maintenance trial of rovalpituzumab tesirine in extensive-stage small cell lung cancer
NL-OMON50134Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rovalpituzumab tesirine in small cell lung cancer (SCLC), sponsored by AbbVie Inc. Started Jan 2018; status: completed.
02
Drugs
rovalpituzumab tesirine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON50134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50134.